TY - JOUR
KW - Adrenal Cortex Hormones
KW - Disease Progression
KW - *Eosinophilia/drug therapy
KW - Humans
KW - Inflammation/chemically induced
KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy
KW - chronic obstructive pulmonary disease
KW - disease burden
KW - eosinophils
KW - exacerbations
KW - health care resource utilization
AU - S. Chen
AU - M. Miravitlles
AU - C. Rhee
AU - I. Pavord
AU - R. Jones
AU - V. Carter
AU - B. Emmanuel
AU - M. Alacqua
AU - D. Price
AD - BioPharmaceuticals Medical, Respiratory & Immunology, AstraZeneca, Gaithersburg, MD, USA.
Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
College of Medicine, Seoul St Mary's Hospital, the Catholic University of Korea, Seoul, South Korea.
Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Faculty of Health, University of Plymouth, Plymouth, UK.
Observational and Pragmatic Research Institute, Singapore, Singapore.
BioPharmaceuticals Medical, Respiratory & Immunology, AstraZeneca, Cambridge, UK.
Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
AN - 36110306
BT - Int J Chron Obstruct Pulmon Dis
C2 - PMC9470244
DO - 10.2147/copd.s378649
DP - NLM
ET - 2022/09/17
LA - eng
N1 - 1178-2005
Chen, Stephanie
Miravitlles, Marc
Orcid: 0000-0002-9850-9520
Rhee, Chin Kook
Pavord, Ian D
Orcid: 0000-0002-4288-5973
Jones, Rupert
Carter, Victoria
Emmanuel, Benjamin
Alacqua, Marianna
Price, David B
Orcid: 0000-0002-9728-9992
Journal Article
Observational Study
New Zealand
Int J Chron Obstruct Pulmon Dis. 2022 Sep 9;17:2187-2200. doi: 10.2147/COPD.S378649. eCollection 2022.
PY - 2022
SN - 1176-9106 (Print)1176-9106
SP - 2187
EP - 2200
T2 - Int J Chron Obstruct Pulmon Dis
TI - Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy
VL - 17
ER -